DrugPatentWatch Database Preview
GOPRELTO Drug Profile
» See Plans and Pricing
When do Goprelto patents expire, and when can generic versions of Goprelto launch?
Goprelto is a drug marketed by Genus Lifesciences and is included in one NDA. There are six patents protecting this drug.
The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this compound. Additional details are available on the cocaine hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Goprelto
Goprelto will be eligible for patent challenges on December 14, 2021. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 14, 2022. This may change due to patent challenges or generic licensing.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for GOPRELTO
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GOPRELTO |
| DailyMed Link: | GOPRELTO at DailyMed |
Generic Entry Opportunity Date for GOPRELTO
Generic Entry Date for GOPRELTO*:
Constraining patent/regulatory exclusivity:
FDA exclusivity NDA:
Dosage:
SOLUTION;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for GOPRELTO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Genus Lifesciences | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
